Detalhe da pesquisa
1.
Profiling the immune landscape in mucinous ovarian carcinoma.
Gynecol Oncol
; 168: 23-31, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368129
2.
Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.
J Transl Med
; 20(1): 564, 2022 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36474270
3.
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Gynecol Oncol
; 164(2): 437-445, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34955238
4.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718565
5.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086926
6.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740262
7.
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Gynecol Oncol
; 161(2): 374-381, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637349
8.
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
Gynecol Oncol
; 163(2): 398-407, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34481610
9.
A healthy lifestyle and survival among women with ovarian cancer.
Int J Cancer
; 147(12): 3361-3369, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32542708
10.
Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
CA Cancer J Clin
; 63(6): 419-37, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24590861
11.
10-year performance of four models of breast cancer risk: a validation study.
Lancet Oncol
; 20(4): 504-517, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30799262
12.
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Breast Cancer Res
; 21(1): 52, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999962
13.
Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).
Breast Cancer Res
; 21(1): 128, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31779655
14.
Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
Int J Cancer
; 145(2): 370-379, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30725480
15.
Do all patients with recurrent ovarian cancer need systemic therapy?
Cancer
; 125 Suppl 24: 4602-4608, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31967677
16.
Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).
Breast Cancer Res
; 20(1): 132, 2018 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30390716
17.
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.
Oncologist
; 23(2): 203-213, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29118265
18.
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Gynecol Oncol
; 150(3): 527-533, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30054102
19.
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
Qual Life Res
; 27(1): 59-74, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29248998
20.
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 145(1): 122-129, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28190649